198 completed. 198 Phase 2, 47 Phase 1, 22 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 198 | Completed 198 |
| Phase 1 | 47 | Completed 47 |
| Phase 3 | 22 | Completed 22 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis Placebo Tablet(s), DLBS1033 - Pneumonia, Sepsis | Phase 2 | Completed | Universitas Sebelas Maret | 50 | 2025-08-14 | 2026-10-23 |
| A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) Foscenvivint - Liver Cirrhosis | Phase 2 | Completed | Kiminori Kimura, MD | 5 | 2024-05-08 | 2026-05-01 |
| Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) Lusutrombopag Oral Tablet - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 17 | 2024-04-17 | 2025-12-19 |
| Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 25 | 2024-03-18 | 2025-01-22 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) TAK-755 - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 2 | Completed | Takeda | 29 | 2023-07-21 | 2026-06-17 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness FibCLOT, RiaSTAP - Hypofibrinogenemia, Surgical Blood Loss | Phase 2 | Completed | IRCCS Policlinico S. Donato | 40 | 2023-03-20 | 2024-02-28 |
| A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia CM313 Injection - Immune Thrombocytopenia, Treatment | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2023-01-22 | 2025-02-24 |
| ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase Aspirin - Purpura, Thrombocytopenic | Phase 2 | Completed | University Hospital, Toulouse | 4 | 2023-01-16 | 2025-12-31 |
| Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 32 | 2023-01-09 | 2024-01-02 |
| Immunomodulation With Eltrombopag in ITP Eltrombopag (Revolade®), standard therapy (without eltrombopag): HD-DXM - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Completed | University Children's Hospital Basel | 2 | 2022-09-01 | 2024-10-15 |
| KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ - Hemophilia | Phase 2 | Completed | Suzhou Alphamab Co., Ltd. | 24 | 2022-07-07 | 2024-12-30 |
| A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection FRSW117 - Severe Hemophilia A | Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 15 | 2022-04-14 | 2023-05-15 |
| A Study of Zanubrutinib in Patients With ITP Zanubrutinib - Immune Thrombocytopenia, Bruton Tyrosine Kinase | Phase 2 | Completed | Peking University People's Hospital | 20 | 2022-01-01 | 2023-10-10 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 81 | 2021-12-15 | 2025-09-22 |
| A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor STSP-0601 for Injection - Hemophilia | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 77 | 2021-10-12 | 2024-09-19 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) SAR445088 (BIVV020) - Immune Thrombocytopenia (ITP) | Phase 2 | Completed | Bioverativ, a Sanofi company | 12 | 2021-02-04 | 2025-09-10 |
| Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC 5-fluorouracil, Docetaxel - Gastric Cancer, Bone Marrow Metastasis | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 24 | 2021-01-15 | 2024-03-25 |
Showing 20 of 198. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (53) · Thrombocythemia, Essential (52) · Polycythemia Vera (46) · Hemophilia A (43) · Primary Myelofibrosis (42) · Myeloproliferative Disorders (36) · Leukemia, Myelomonocytic, Chronic (22) · Leukemia, Myeloid, Acute (21) · Leukemia, Lymphocytic, Chronic, B-Cell (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Leukemia (19) · Lymphoma, Non-Hodgkin (18) · Myelodysplastic Syndromes (18) · Multiple Myeloma (17) · Leukemia, Myeloid, Accelerated Phase (16)
Hemic and Lymphatic Diseases (198) · Hematologic Diseases (186) · Hemorrhagic Disorders (175) · Blood Platelet Disorders (120) · Pathologic Processes (110) · Pathological Conditions, Signs and Symptoms (110) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (92) · Immune System Diseases (88) · Genetic Diseases, Inborn (74) · Cytopenia (72) · Blood Coagulation Disorders, Inherited (71) · Hemorrhage (65) · Signs and Symptoms (65) · Skin Manifestations (65)
Cyclophosphamide (15) · Peripheral Blood Stem Cell Transplantation (14) · fludarabine phosphate (14) · Rituximab (12) · eltrombopag (12) · Busulfan (11) · Factor VIII (10) · Tacrolimus (9) · Methotrexate (8) · Mycophenolic Acid (8) · Whole-Body Irradiation (8) · romiplostim (8) · Antilymphocyte Serum (6) · Cyclosporine (6) · Dexamethasone (5)
Fred Hutchinson Cancer Center (11) · Baxalta now part of Shire (10) · CSL Behring (9) · Amgen (4) · GlaxoSmithKline (4) · National Cancer Institute (NCI) (4) · Novartis Pharmaceuticals (4) · Pfizer (4) · Bayer (3) · Hospital Universitario Dr. Jose E. Gonzalez (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Peking University People's Hospital (3) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (3) · Weill Medical College of Cornell University (3) · Assistance Publique - Hôpitaux de Paris (2)
United States (116) · United Kingdom (39) · Germany (31) · Italy (30) · France (26) · Canada (22) · Spain (22) · Poland (20) · China (18) · Australia (16) · Bulgaria (14) · Japan (14) · Austria (13) · Russia (13) · Israel (11)
David Gomez-Almaguer, MD (3) · Margaret V. Ragni, MD, MPH (3) · Alessandro Rambaldi, MD (2) · H. Joachim Deeg, MD (2) · Lei Zhang, MD (2) · Lei Zhang, Ph.D (2)
PMID 19216617, PMID 24802775, PMID 32499241, PMID 35075289, PMID 40386832, PMID 41637644, PMID 42698050, PMID 11468154, PMID 12353309, PMID 15374882, PMID 15389904, PMID 17058240, PMID 17515510, PMID 18046028, PMID 19096013, PMID 19208097, PMID 19231632, PMID 19731307, PMID 19804533, PMID 19841031, PMID 20058208, PMID 20576011, PMID 20651074, PMID 20841509, PMID 21636861, PMID 21833452, PMID 22223819, PMID 22470921, PMID 22475545, PMID 22764744, PMID 22915649, PMID 22943924, PMID 23238591, PMID 23279219, PMID 23281974, PMID 23452139, PMID 23492914, PMID 23753021, PMID 24262278, PMID 24362550, PMID 24802773, PMID 24903629, PMID 25132654, PMID 25458735, PMID 25495591, PMID 25623166, PMID 25762180, PMID 26157075, PMID 26210442, PMID 26332546
2019 (5), 2018 (4), 2023 (4), 2009 (3), 2016 (3), P30CA015704 (3), 2014 (2), 2015 (2), 2017 (2), P01CA015396 (2), P01CA018029 (2), P30CA006973 (2), P30CA015083 (2), 2004 (1), 2008 (1)